Filing Flows › Bristol Myers Squibb (BMY) › Q2 2025
Bristol Myers Squibb (BMY) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 31, 2025
Bristol Myers Squibb (BMY) reported revenue of $12.3B for the second quarter 2025 (Q2 2025), +0.6% from a year earlier and +10% from the quarter before. Operating margin was 14.5%, net earnings $1.3B (10.7% of revenue).
Bristol Myers Squibb, Q2 2025: revenue $12.3B (+0.6% year over year), operating margin 14.5%, net earnings $1.3B, operating cash flow $3.9B. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.3B | +10% | +0.6% |
| Operating profit | $1.8B | -40% | +38% |
| Net earnings | $1.3B | -47% | -22% |
| Operating cash flow | $3.9B | +100% | +68% |
| Free cash flow | $3.6B | +110% | +72% |
What changed
Revenue was $12.3B in Q2 2025, up 1% year over year and up 10% from the previous quarter. Legacy Portfolio was the largest line at 46% of revenue. Breyanzi added $0.19B year over year (up 125%), 281% of the total change. Revlimid declined 38%.
Operating profit was $1.8B, a 14.5% margin (up 3.9 points year over year). Of the extra revenue versus a year earlier, 716% reached operating profit, above the 11% margin then. Total costs fell 4% while revenue rose 1%. Net earnings were $1.3B, down 22% year over year. The effective tax rate was 25.9%.
Operating cash flow was $3.9B (up 68% year over year), 298% of net earnings. Non-cash charges added back $1.0B of depreciation and amortization and $0.14B of share-based compensation. Working capital and other items added $1.5B. Capital expenditures of $0.36B left free cash flow of $3.6B.
Questions
What was Bristol Myers Squibb's revenue in the second quarter 2025?
Bristol Myers Squibb (BMY) reported revenue of $12.3B for the second quarter 2025 (Q2 2025), +0.6% from a year earlier and +10% from the quarter before.
Was Bristol Myers Squibb profitable in the second quarter 2025?
Operating profit was $1.8B (14.5% of revenue) and net earnings $1.3B.